Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.48 |
| ▸ | MAT2A | P31153 | 2/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.37 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23433 | 0.86 | DHODH (0.46) | DHODHKDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL20784 | 0.83 | DHODH (0.51) | DHODHSORT1KDM4EALDH1A1HPGD | |
| SCHEMBL24084 | 0.81 | DHODH (0.46) | DHODHKDM4ETDP1EIF4A1 | |
| Hydrochloric Acid SCHEMBL22807 | 0.81 | DHODH (0.49) | DHODHSORT1KDM4EALDH1A1CYP2C19 | |
| SCHEMBL20906 | 0.80 | MLYCD (0.40) | MAT2ASORT1USP2PTGFRRORC | |
| SCHEMBL20754 | 0.79 | KCNQ3 (0.47) | KDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL30824651 | 0.79 | KCNQ3 (0.47) | KDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL21014 | 0.79 | TP53BP1 (0.37) | MAT2AKDM4EUSP2HSD17B10PTGFR | |
| SCHEMBL22574 | 0.79 | KCNQ3 (0.56) | KDM4EALDH1A1TDP1 | |
| SCHEMBL21561 | 0.78 | NAMPT (0.38) | MAT2AKDM4EUSP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073862-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2609083-B1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2014-03-20 | — | — | US | disclosed |
| US-8653101-B2 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2609083-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025236-A1 | SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080867-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | DHODH 2566/4885MAT2A 3594/4885SORT1 4835/4885 |
| US-20120053205-A1 | Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | DHODH 2566/4885MAT2A 3594/4885SORT1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.